Leading blood plasma group CSL (ASX: CSL) has been making the most of the recent fall in its share price with continued on market purchases of its shares. Since the latest buy-back was implemented in October 2012 over 14 million shares have been re-purchased and cancelled at a total cost of around $820 million.
With CSL shares trading at their lowest level since April it would appear an opportune time to boost the daily buy-back amount, which in the last few days has been running at around a $10 million spend. Other health sector stocks to be conducting buy-backs at present include wholesaler Sigma Pharmaceuticals (ASX: SIP) and medical products supplier ITL (ASX: ITD). As the chart below shows, there is often a correlation between companies conducting buy-backs and share price outperformance.
Source: Google Finance
Foolish takeaway
Buy-backs can be a great way for management to increase shareholder value. It can be worth investors investigating companies that announce buy-backs given the potential for these stocks to outperform.
In the market for high yielding ASX shares? Get "3 Stocks for the Great Dividend Boom" in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!
More reading
Motley Fool contributor Tim McArthur has no financial interest in any company mentioned in this article.
